Top Markets
Coin of the day
Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO
Clasificación en acciones #6421
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Precio por acción
$32.61
Capitalización bursátil
$2.06B
Cambio (1 día)
-1.30%
Cambio (1 año)
95.15%
País
US
Comercio Zenas BioPharma, Inc. (ZBIO)

Categoría

Historial de desdoblamientos de acciones de Zenas BioPharma, Inc. (ZBIO)
La acción Zenas BioPharma, Inc. (símbolo: ZBIO) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 27, 2026.
Una acción ZBIO comprada antes de Aug 27, 2026 equivaldría hoy a 0 acciones ZBIO.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH